CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the SVB Securities Global Biopharma Conference at 10:00 a.m. ET on Thursday, February, 16, 2023.
A live webcast of this presentation can be found here and will also be available on the Investor Relations page of the Wave Life Sciences corporate website at http://ir.wavelifesciences.com. Replays of this presentation will be archived and available on the site for a limited time following the event.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.
Investor Contact:
Kate Rausch
617-949-4827
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Alicia Suter
617-949-4817
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$14.83 |
| Daily Change: | -0.06 -0.40 |
| Daily Volume: | 862,129 |
| Market Cap: | US$1.850B |
November 26, 2024 November 12, 2024 October 30, 2024 October 16, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
